图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
真核基因表达评论综述™
影响因子: 1.841 5年影响因子: 1.927 SJR: 0.627 SNIP: 0.516 CiteScore™: 1.96

ISSN 打印: 1045-4403
ISSN 在线: 2162-6502

真核基因表达评论综述™

DOI: 10.1615/CritRevEukarGeneExpr.v10.i2.10
14 pages

Therapeutic Angiogenesis: A Case for Targeted, Regulated Gene Delivery

Keith A. Webster
Department of Molecular and Cellular Pharmacology, University of Miami Medical Center, 1600 NW 10th Avenue, RMSB 6038, Miami, FL 33136

ABSTRACT

Blood and vascular disorders underlie a plethora of pathological conditions and are the single most frequent cause of human disease. Eliminated or restricted blood flow to tissues as a result of vessel dysfunction results in the disruption of oxygen and nutrient delivery and the accumulation of waste metabolites. Cells cannot survive extended severe ischemia but may be able to adapt to a moderate condition where diffusion to and from bordering nonischemic regions sustain vital functions. Under this condition, secondary functions of affected cells are likely to be impaired and a new metabolic equilibrium is established, determined by the level of cross-diffusion. In tissues with a normally high metabolic turnover such as skeletal and cardiac muscle, ischemia causes hypoxia, acidosis, and depressed function (contractility). The treatment possibilities for tissue ischemia resulting from vascular disease are limited. Lipid-lowering agents may help slow the progression of vessel disease in some instances, but surgical reconstruction may be the only option in advanced stages, and even this is not always an option. An alternative and rather obvious strategy to treat ischemia is to activate endogenous angiogenic or vasculogenic pathways and stimulate revascularization of the tissue. The feasibility of such a strategy has now been established through the results of studies over the past decade and a new discipline called therapeutic angiogenesis has emerged. This review focuses on the application of therapeutic angiogenesis for treating peripheral limb ischemia and coronary artery diseases; the author traces the evidence supporting the feasibility of this treatment strategy, its current limitations, and possible directions.


Articles with similar content:

Gut Microbiota: Potential Impact on Chemotherapy-Related Adverse and Therapeutic Effects
Forum on Immunopathological Diseases and Therapeutics, Vol.7, 2016, issue 1-2
M. Salimon, E. Montassier, Yann Touchefeu
Functional Properties of Human Embryonic Stem Cell−Derived Cardiomyocytes
Critical Reviews™ in Eukaryotic Gene Expression, Vol.20, 2010, issue 1
Naama Zeevi-Levin, Ofer Binah, Joseph Itskovitz-Eldor
Review of Endometriosis Diagnosis through Advances in Biomedical Engineering
Critical Reviews™ in Biomedical Engineering, Vol.46, 2018, issue 3
Ruchi Shah, Ravi P. Jagani
Embryonic and Induced Pluripotent Stem Cells as a Model for Liver Disease
Critical Reviews™ in Biomedical Engineering, Vol.37, 2009, issue 4-5
Alejandro Soto-Gutierrez, Masaki Nagaya, Hiroshi Yagi, Ira J. Fox, Edgar Tafaleng, Stephen C. Strom, Marc C. Hansel
Exercise in the Assessment and Treatment of Patients with Cancer
Critical Reviews™ in Physical and Rehabilitation Medicine, Vol.10, 1998, issue 1
Roy J. Shephard, P. N. Shek